法国CRS+HIPEC治疗腹膜表面恶性肿瘤的经验  

Experience of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies in France

作　　者：Olivier Glehen 安松林(翻译) 李雁(审校) Olivier Glehen(Department of General Surgery and Oncology,Lyon South Hospital,University of Lyon I,Lyon,France;Department of Endocrine Surgery,Lyon South Hospital,University of Lyon I,Lyon,France)

机构地区：[1]里昂第一大学里昂南医院普通外科肿瘤外科 [2]里昂第一大学里昂南医院内分泌外科 [3]不详

出　　处：《中国肿瘤临床》2022年第24期1303-1307,共5页Chinese Journal of Clinical Oncology

摘　　要：近30年来,腹膜癌的治疗取得了快速发展,部分病例接受肿瘤细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC),可获长期生存,甚至临床治愈。法国在这一领域作出了历史性贡献,积极推动国际合作。本文主要介绍法国罕见病协作网(RENAPE和BIG-RENAPE)的发展壮大过程,在腹膜肿瘤学领域取得的历史性成就,在新时代所面临的机遇和挑战,包括腹膜肿瘤发生、发展的分子机制、分子病理诊断、腹膜转移的高危因素、CRS+HIPEC的适应证等,需要法国和全球腹膜表面恶性肿瘤领域学者共同面对新时代的机遇和挑战。Management of cancer peritoneal metastasis(PM) has evolved enormously over the past three decades. Long-term survival and even clinical cure could be achieved in some selected PM patients treated by cytoreductive surgery(CRS) plus hyperthermic intraperitoneal chemotherapy(HIPEC). French experts have made historic contributions in this field, and have played a leading role in international collaborations. This paper highlighted the establishment, development, and historical achievements by the French collaborating networks(RENAPE and BIG-RENAPE), and emerging challenges and opportunities in the new era of peritoneal surface oncology, including peritoneal tumor genesis, molecular mechanism of development, molecular pathological diagnosis, high-risk factors of peritoneal metastasis, indications for CRS+HIPEC, etc., it is necessary for French and global scholars in the field of peritoneal surface malignancy to face the opportunities and challenges of the new era.

关 键 词：腹膜恶性肿瘤 肿瘤细胞减灭术 腹腔热灌注化疗 RENAPE BIG-RENAPE 

分 类 号：R735.5[医药卫生—肿瘤]